Ramón Cacabelos García-rekin lankidetzan egindako argitalpenak (6)

2011

  1. Combination treatment in Alzheimer's disease: Results of a randomized, controlled trial with cerebrolysin and donepezil

    Current Alzheimer Research, Vol. 8, Núm. 5, pp. 583-591

  2. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

    European Journal of Neurology, Vol. 18, Núm. 1, pp. 59-68

2009

  1. Reduced TNF- and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin

    International Journal of Neuropsychopharmacology, Vol. 12, Núm. 7, pp. 867-872

2007

  1. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease

    Neurobiology of Aging, Vol. 28, Núm. 4, pp. 533-536

2006

  1. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

    European Journal of Neurology, Vol. 13, Núm. 1, pp. 43-54

2003

  1. Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: An exploratory study

    International Clinical Psychopharmacology, Vol. 18, Núm. 5, pp. 271-278